New Stago Webinar announcement

How to diagnose and manage Heparin-Induced Thrombocytopenia (HIT)?
by Pr Yves Gruel – Professor of Hematology, Trousseau Hospital and University Francois Rabelais, Tours (France)

Type II Heparin-Induced Thrombocytopenia (HIT) is an immune-mediated adverse effect of heparin treatment. Although rare, this complication can be serious and possibly life threatening.

Approximately one third of hospitalized patients are exposed to heparins. It is therefore of great importance to know how to:

  • diagnose HIT in order to identify the patients who will benefit from an alternative anticoagulant treatment
  • avoid HIT overdiagnosis to minimize the risks of bleedings and the costs associated with the use of alternative anticoagulants

This webinar will focus on HIT pathophysiology, and will outline the necessity of an accurate diagnosis and how it can be achieved. Alternative anticoagulant treatment options will also be discussed.

This 30-minute presentation will be followed by a 15-minute live chat with the speaker.

Pr Gruel is the Head of the Hematology Department at Trousseau University Hospital in Tours and is also leading the Hemophilia Care Center.
Apart from his clinical activity focusing on bleeding and thrombotic disorders, his main research topics are today heparin-induced thrombocytopenia (HIT) and the role of specific coagulation proteins in cancer.

He is currently the President of GEHT (French study Group on Haemostasis and Thrombosis), and Chairman of the ISTH Scientific and Standardization Committee on Platelet Immunology.

Save the date! Friday January 31st 2014 at 4:00 p.m. CET (Central European Time)

To attend this webinar, please register at www.stagowebinars.com.